Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when THC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTenet Healthcare reports Q2 net income of $826M, raises FY guidance, authorizes $2B buyback
Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 net income $826M ($9.84/share) vs. $288M ($3.14/share) in Q2 2025; raised FY 2026 Adjusted EBITDA guidance to $4.83–$5.03B (up $295M at midpoint) and Adjusted Free Cash Flow to $2.2 million–$3.025B (up $225M).
Exhibit 99.1 view on EDGAR → -
high
Board authorized $2.0B increase to share repurchase program, bringing total remaining authorization to $2.13B as of July 23, 2026; repurchased 5.68M shares for $1.042B in Q2 2026.
Exhibit 99.1 view on EDGAR → -
high
Q2 2026 Consolidated Adjusted EBITDA rose 16.3% to $1.304B with 23.2% margin; Hospital segment margin expanded to 18.0% from 15.6% in Q2 2025 despite payer mix headwinds.
Exhibit 99.1 view on EDGAR → -
medium
Hospital segment recognized $92M favorable pre-tax Medicaid supplemental revenues related to prior years in Q2 2026, up from $70M in Q2 2025.
Exhibit 99.1 view on EDGAR → -
medium
Same-hospital admissions rose 2.3% and adjusted admissions increased 2.6% in Q2 2026; net patient service revenue per adjusted admission grew 3.3%, driven by commercial employer strength.
Exhibit 99.1 view on EDGAR →
Summary
Tenet Healthcare delivered a strong second quarter 2026, with net income tripling year-over-year to $826 million ($9.84 per diluted share) from $288 million ($3.14 per share) in Q2 2025.
The company raised its full-year 2026 Adjusted EBITDA guidance by $295 million at the midpoint to $4.83–$5.03 billion and increased Adjusted Free Cash Flow guidance by $225 million to $2.2 million–$3.025 billion, reflecting robust same-store revenue growth and effective expense management.
Consolidated Adjusted EBITDA climbed 16.3% to $1.304 billion with a 23.2% margin, while the Hospital segment's margin expanded 240 basis points to 18.0% despite unfavorable payer mix from lower exchange admissions. The Board authorized a $2.0 billion increase to the share repurchase program, bringing total remaining authorization to $2.13 billion. In Q2 2026 alone, Tenet repurchased 5.68 million shares for $1.042 billion, underscoring management's confidence in the business trajectory and commitment to returning capital to shareholders. The Hospital segment also recognized $92 million in favorable Medicaid supplemental revenues related to prior years, up from $70 million in the prior-year quarter, contributing to the strong EBITDA performance. Same-hospital admissions rose 2.3% and adjusted admissions increased 2.6%, with net patient service revenue per adjusted admission growing 3.3% on commercial employer strength.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Tenet Healthcare reported Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On July 23, 2026, Tenet Healthcare Corporation (the “Company”) issued a press release reporting the financial results of the Company for the quarter ended June 30, 2026.
Tenet Healthcare disclosed its second quarter 2026 financial results through a press release. The 8-K body does not contain specific financial metrics; those would be in the attached Exhibit 99.1 press release, which is not included in the provided text.
Event · Exhibit 99.1
Tenet reported Q2 2026 earnings with net income of $826M ($9.84/share), raised full-year guidance, and announced a $2B share repurchase authorization.
Added in current filing · view on EDGAR → · paraphrased
Second quarter 2026 Consolidated Adjusted EBITDA increased 16.3% over second quarter 2025 to $1.304 billion; Second quarter 2026 Adjusted EBITDA margin was 23.2% ... Hospital Adjusted EBITDA margin increased to 18.0% in second quarter 2026 compared to 15.6% in second quarter 2025 despite payer mix headwinds
Q2 2026 Consolidated Adjusted EBITDA rose 16.3% to $1.304 billion with a 23.2% margin. The Hospital segment's Adjusted EBITDA margin expanded to 18.0% from 15.6% in Q2 2025, despite unfavorable payer mix from lower exchange admissions. The Ambulatory segment posted $542 million Adjusted EBITDA, up 8.8% year-over-year.
Added in current filing · view on EDGAR →
Board of Directors authorized a $2.0 billion increase to the share repurchase program ... With this new authorization, the Company has $2.13 billion remaining under its repurchase authorizations as of July 23, 2026. Repurchases will be made at management's discretion from time to time in the open market or through privately negotiated transactions, subject to market conditions and other relevant factors.
Tenet's Board authorized a $2.0 billion increase to the share repurchase program, bringing total remaining authorization to $2.13 billion as of July 23, 2026. In Q2 2026, the company repurchased 5.68 million shares for $1.042 billion; for the six months ended June 30, 2026, it repurchased 7.02 million shares for $1.360 billion.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 24, 2026 · How we verify